Stock comparison
Genmab A/S
Organon &
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
OGN
Organon &
Market cap
$3.53B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | OGN | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 57C | GMAB |
| Benjamin Graham | 64C | 78B | OGN |
| Philip Fisher | 48D | 38D | GMAB |
| Peter Lynch | 25F | 27F | OGN |
| Joel Greenblatt | 76B | 21F | GMAB |
| Charlie Munger | 68C | 48D | GMAB |
| Terry Smith | 71C | 46D | GMAB |
Side-by-side metrics
| Metric | GMAB | OGN |
|---|---|---|
| Market cap | $16.5B | $3.53B |
| P/E (TTM) | 6.2x | 14.2x |
| EV/EBIT | 12.0x | 8.5x |
| ROIC (TTM) | 43.78% | 5.16% |
| Gross margin | 93.88% | 53.11% |
| Net margin | 18.23% | 3.99% |
| Revenue CAGR 5y | -18.45% | -0.35% |
| EPS CAGR 5y | -23.48% | -39.38% |
| Debt / Equity | 0.1x | 9.5x |
| Dividend yield | 0.0% | 0.6% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- Debt / Equity0.1xvs 9.5x+99%
- ROIC (TTM)43.78%vs 5.16%+88%
- Market cap$16.5Bvs $3.53B+79%
- Net margin18.23%vs 3.99%+78%
OGN leads on
- Dividend yield0.6%vs 0.0%+100%
- Revenue CAGR 5y-0.35%vs -18.45%+98%
- EV/EBIT8.5xvs 12.0x+29%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.